MYOG

Myogen (MYOG)

Myogen

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MYOG

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2006/11/18	06 : 02	Business Wire	Gilead Sciences Completes Acquisition of Myogen	NASDAQ:MYOG	Myogen
2006/11/06	22 : 00	Business Wire	Darusentan Data to Be Presented at AHA 2006 -- Chicago	NASDAQ:MYOG	Myogen
2006/10/18	05 : 00	Business Wire	Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan	NASDAQ:MYOG	Myogen
2006/10/10	21 : 00	Business Wire	Four Ambrisentan Studies to Be Presented at Chest 2006 -- Salt Lake City	NASDAQ:MYOG	Myogen
2006/10/03	01 : 11	PR Newswire (US)	Seven Summits Research Releases Comments on GOOG, ABX, HET, CBS, and MYOG	NASDAQ:MYOG	Myogen
2006/10/02	20 : 00	Business Wire	Gilead Sciences to Acquire Myogen, Inc. for $2.5 Billion	NASDAQ:MYOG	Myogen
2006/09/20	21 : 30	Business Wire	Myogen to Present at the UBS Global Life Sciences Conference	NASDAQ:MYOG	Myogen
2006/09/07	21 : 00	Business Wire	Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension	NASDAQ:MYOG	Myogen
2006/09/06	21 : 00	Business Wire	The American Lung Association and Myogen Announce Pulmonary Arterial Hypertension Educational Partnership	NASDAQ:MYOG	Myogen
2006/08/08	05 : 00	Business Wire	Myogen Reports 2006 Second Quarter Results	NASDAQ:MYOG	Myogen
2006/07/25	20 : 45	Business Wire	Myogen to Announce 2006 Second Quarter Results on August 7, 2006	NASDAQ:MYOG	Myogen
2006/07/11	21 : 30	Business Wire	Myogen Announces Extension of Drug Discovery Collaboration	NASDAQ:MYOG	Myogen
2006/06/08	20 : 30	Business Wire	Myogen to Present at the Goldman Sachs Global Healthcare Conference	NASDAQ:MYOG	Myogen
2006/06/05	21 : 01	Business Wire	Myogen Initiates Phase 3 Clinical Trial of Darusentan in Patients with Resistant Hypertension	NASDAQ:MYOG	Myogen
2006/05/24	19 : 30	Business Wire	Ambrisentan Phase 3 ARIES-2 PAH Data Presented At ATS 2006 -- San Diego; Significant Improvement in Six-Minute Walk Distance an	NASDAQ:MYOG	Myogen
2006/05/08	20 : 00	Business Wire	Myogen Reports 2006 First Quarter Results	NASDAQ:MYOG	Myogen
2006/05/04	05 : 00	Business Wire	Myogen Reports Results for the Integrated Analysis of ARIES-1 and ARIES-2 Pivotal Trials of Ambrisentan in Pulmonary Arterial H	NASDAQ:MYOG	Myogen
2006/04/21	20 : 00	Business Wire	Myogen to Announce 2006 First Quarter Results on May 8, 2006	NASDAQ:MYOG	Myogen
2006/04/20	05 : 00	Business Wire	Myogen to Present at the Leerink Swann Vascular Modlulation Conference	NASDAQ:MYOG	Myogen
2006/04/11	01 : 36	PR Newswire (US)	Seven Summits Research releases comments on AAPL, EBAY, HAL, MYOG, and URBN	NASDAQ:MYOG	Myogen
2006/04/10	20 : 00	Business Wire	Myogen Reports Positive Top Line Results for Second Ambrisentan Pivotal Phase 3 Trial in Pulmonary Arterial Hypertension; ARIES	NASDAQ:MYOG	Myogen
2006/03/10	00 : 57	PR Newswire (US)	Seven Summits Research Releases Comments on MRVL, DELL, SGP, GENZ, and MYOG	NASDAQ:MYOG	Myogen
2006/03/09	22 : 00	Business Wire	Ambrisentan Receives FDA Fast Track Designation for PAH Development	NASDAQ:MYOG	Myogen
2006/03/07	06 : 10	Business Wire	Myogen Reports 2005 Results	NASDAQ:MYOG	Myogen
2006/03/02	22 : 00	Business Wire	Ambrisentan ARIES-2 Data to Be Presented at ATS 2006 -- San Diego	NASDAQ:MYOG	Myogen
2006/03/01	06 : 00	Business Wire	Myogen to Present at the Citigroup Small & Mid-Cap Conference	NASDAQ:MYOG	Myogen
2006/02/13	22 : 30	PR Newswire (US)	Myogen Reports Positive Top Line Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension	NASDAQ:MYOG	Myogen
2006/02/07	00 : 12	PR Newswire (US)	NASDAQ Hosts First-Ever Investor Conference in London for Small Cap Companies	NASDAQ:MYOG
2006/02/06	22 : 00	PR Newswire (US)	Myogen to Announce 2005 Results on March 6, 2006	NASDAQ:MYOG	Myogen
2006/02/03	06 : 30	PR Newswire (US)	Myogen Announces Sale of Myogen GmbH	NASDAQ:MYOG	Myogen